Molecularly targeted therapies are increasingly relevant in clinical oncology, as they enable the selective modulation of specific biologic targets—such as enzymes or receptors—by inhibiting or ...
Figure][1] Jason S. Lewis, PhD Professor Jason S. Lewis holds the Emily Tow Chair at Memorial Sloan Kettering (MSK) in New York. He serves as deputy director of the Sloan Kettering Institute, ...
Incidental findings from PET are common, induce unnecessary patient anxiety, and incur substantial costs to the health care system, with further diagnostic clarification potentially delaying important ...
The second Society of Nuclear Medicine and Molecular Imaging (SNMMI) AI Summit, organized by the SNMMI AI Task Force, took ...
Radiopharmaceuticals represent a promising new frontier in cancer therapy. In the United States, cancer is the second leading cause of death. There is an urgent need to develop new therapies to meet ...
The PSMA-targeting ligand 177 Lu-PSMA-617 was prepared in compliance with good manufacturing practices. Radio–high-performance liquid chromatography as the primary method of quality control was ...
We took a novel approach to testing between the competing models of Aβ accumulation: we used the whole-cortex Aβ profile derived from the longitudinal study of Jack et al. (in which the patients did ...
The recently released Biograph mMR is the first commercially available integrated whole-body PET/MR scanner. There are considerable advantages to integrating both modalities in a single scanner that ...
Journal of Nuclear Medicine April 2025, jnumed.124.269132; DOI: https://doi.org/10.2967/jnumed.124.269132 ...
Theranostic strategies involve select radionuclides that allow diagnostic imaging and tailored radionuclide therapy in the same patient. An example of a Food and Drug Administration–approved ...
RECIST was developed in 2000 by the National Cancer Institute, European Organization for Research and Treatment of Cancer, and National Cancer Institute of Canada, with revision to RECIST 1.1 in 2009 ...
There is a significantly growing interest in diagnostic and therapeutic radiopharmaceuticals, and it is foreseeable that an unprecedented number of patients will need to be treated with new nuclear ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results